Skip to content
About Us

Making heart valve treatment non-invasive

Cardiawave develops Valvosoft®, a Non-Invasive Ultrasound Therapy (NIUT) for calcific aortic stenosis – the most prevalent heart valve disease in adults.

2014

Cardiawave founded from INSERM, CNRS, ESPCI and HEGP research

100

Patients treated in premarket clinical investigations

4

European countries in clinical investigations

25

People in Levallois-Perret

2019

EN ISO 13485:2016 certified quality management system

2025

Valvosoft® CE marking

THE GENESIS

Born from world-class French research

Cardiawave was founded in late 2014 through a longstanding collaboration between the academic laboratories Physics for Medicine Paris and Langevin Institute (INSERM/CNRS/ESPCI), leaders in ultrasound imaging and therapy, and the Georges Pompidou European Hospital (HEGP AP-HP), a leading center in valve disease and cardiac ultrasound imaging.

The project received support from the “Investissements d’Avenir” Program as part of the World Innovation Contest and I-Nov program, funding from the French National Research Agency (ANR-16-RHUS-0003_STOP-AS and ANR-17-CE19-0019-03), and the European Commission’s Horizon 2020 SME Instrument (grant no. 829492). Cardiawave was named a winner of French Tech Health 20, joined La French Care in 2023, and became a member of Medtech in France and France Biotech in 2024, as well as the Medicen competitiveness cluster.

Certified EN ISO 13485:2016  since 2019, Cardiawave developed Valvosoft®, a non-invasive focused ultrasound therapy (NIUT) medical device for the treatment of calcific Aortic Stenosis (AS), the most prevalent heart valve disease in adults and a major cause of cardiovascular mortality worldwide.

Cardiawave’s breakthrough Valvosoft® therapy was validated in the Pivotal study published in Circulation in August 2026 (DOI: 10.1161/CIRCULATIONAHA.125.077582), further supporting the therapy’s safety profile and clinical efficacy and contributing to CE marking of Valvosoft®. These findings build on the initial first-in-human studies, published in The Lancet in November 2023 (DOI: 10.1016/S0140-6736(23)01518-0), which evaluated the safety and efficacy of Valvosoft® in patients with severe symptomatic aortic stenosis (sSAS) who were not eligible for immediate valve replacement.

Cardiawave’s clinical program included two First-in-Human (FIH) studies (30 and 10 patients, total of 40 patients) (NCT03779620, NCT04665596) and a pivotal study (60 patients)(NCT05235568).

Six-month results of pivotal study were presented at TCT 2024, showing 91.7% of patients free from major adverse cardiovascular events (MACE) at 30 days and at 6 months follow-up 80.5% presented a stabilized or improved cardiac condition (New York Heart Association class).

Twelve-month results (covering all 3 studies or 100 patients) were presented at EuroPCR 2025: 91.0% free from MACE at 30 days and at 12 months an 85.8% NYHA class improvement or stabilization, an 8.6-point increase in KCCQ score, and a 42.8% average increase in aortic valve area (AVA) compared to natural progression of the disease[1].

Valvosoft® has obtained CE marking in November 2025,  when intended for the treatment of adult patients with severe symptomatic calcific Aortic Stenosis (AS) by non-invasive ultrasound therapy (NIUT). Cardiawave is currently working in collaboration with several European centers, and more than 50 patients have been treated since the beginning of 2026.

 

(1) AVA increases by 0.1cm²/year. Prosperi-Porta, et.al, Arch Cardiovasc Dis, 2023.

Cardiawave's Mission

To improve the quality of patient care by developing medical devices for non-invasive therapies.

Guiding Principles

Core Values

Patient First

  • Patients are at the heart of every decision and every innovation.

Innovation & Progress

  • Advancing the future of cardiovascular care through breakthrough technologies.

Quality

  • Delivering excellence through uncompromising quality and safety standards.

Ethics & Integrity

  • Acting with integrity to earn and maintain lasting trust.

Solidarity & Team Spirit

  • United by a shared mission to transform patient care.

Diversity & Inclusion

  • Embracing diversity as a catalyst for innovation and progress.
Chronology

Milestones

  1. 2026

    Clinical Deployment of Valvosoft® in Europe

    First patients treated in routine clinical practice across several European centers following CE Marking.

  2. 2025

    Valvosoft® CE Marking

    Valvosoft® became the first Non-Invasive Ultrasound Therapy (NIUT) for severe symptomatic aortic stenosisstenosis (sSAS) to obtain CE certification in accordance with the European Regulation (EU) 2017/745 on medcial devices.

  3. 2023

    Completion of Pivotal Study Enrollment

    Completed enrollment of the Valvosoft® Pivotal Study, bringing the total clinical experience to 100 treated patients.

  4. 2023

    Publication in The Lancet

    Clinical results from the First-in-Human studies were published in The Lancet, demonstrating the safety and efficacy of the NIUT sSAS patients who were not recommended for an immediate valve replacement.

  5. 2022

    Completion of First-in-Human Studies

    Successfully treated 40 patients in 3 European centers in 3 countries, demonstrating the feasibility and safety of the technology.

  6. 2014

    Founded

    Cardiawave was established through a collaboration between leading French academic laboratories specializing in therapeutic ultrasound and the Georges Pompidou European Hospital (HEGP).

20 awards and honours since 2014

Recognised by the French government, BPI France, Inserm, the European Commission and the MedTech community.

See all awards & recognition
Leadership & Advisors

Leadership Team & Boards

Carine Schorochoff

CEO

Maurice Delplanque

COO

François Desmarest

CFO

Dirk Pauwels

Clinical Director

Clémence Pupier

QARA SR Manager

Jonathan Freeman

Board Chairman

Carine Schorochoff

CEO

Nicolas Boulay

UI Investor

Jacques Duquesne

Investor

Jean de Gunzburg

Investor

François Levé

Investor

Hardip Thakerar

Independent Director

Michael Zaoui

Investor

Emmanuel Messas

Co-founder, Cardiologist, HEGP

Mathieu Pernot

Physicist, Physics for Medicine Paris

Mickaël Tanter

Physicist, Physics for Medicine Paris

Andreas Baumbach

MD, Prof. of Interventional Cardiology at Barts Heart

Hélène Eltchaninoff

Cardiologist, Rouen University Hospital

Edwin Ho

Director Structural Heart Imaging at Montefiore

Won-Keun Kim

MD, Cardiologist & Deputy Director at UKSH Campus Kiel

Azeem Latib

Head of Interventional Cardiology at Montefiore Health

Roxana Mehran

Prof. of Medicine, Mount Sinai Hospital

Emmanuel Messas

Co-founder, Cardiologist, HEGP

Ehud Schwammenthal

Cardiologist at Sheba Medical Center

Careers

Join Cardiawave

Help us build the future of non-invasive cardiac therapy. We are a passionate team of engineers, scientists and clinicians based in Levallois-Perret, near Paris, in France.

See current openings